http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104606671-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate | 2014-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104606671-B |
| titleOfInvention | Compound lysozyme enrofloxacin injection preparation |
| abstract | The invention provides compound lysozyme enrofloxacin injection preparation. The compound lysozyme enrofloxacin injection preparation combines two antibacterial medicines, namely enrofloxacin and lysozyme, and other components of the preparation are pertinently designed, so that respective advantages of the two antibacterial medicines are complemented. The compound lysozyme enrofloxacin injection preparation directly enters blood circulation, so that the problem of poor oral administration absorption of the lysozyme is solved; in addition, the lysozyme belongs to a biological-source medicine and almost has no side effects, so that the lysozyme is more easily accepted by an animal body after being applied to the animal body and does not generate stress easily; moreover, after the enrofloxacin and the lysozyme form the compound preparation, the dosage of the enrofloxacin can be reduced in the using process, so that drug residues are reduced, the metabolic burden is reduced, as a result, the drug safety is enhanced. |
| priorityDate | 2014-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 89.